Possible Healthcare Reform Losers

Posted on

With the D-day for healthcare reform fast approaching it would be interesting to find out which sectors of the healthcare system will come out as winners and which ones will come out as losers.

Generic medication is expected to take a front sit with the healthcare reform and any pharmaceutical company heavily involved in promoting and marketing branded medication will see their market share eat away as generic medicines will be more preferred. Generic drugs provide the same job as branded ones and they are cheaper, so it makes sense to go with them.

Congress is very concerned about physician owned hospitals and medical establishments self referring patients to themselves. They strongly believe that this will be utilized thereby affecting the quality of healthcare. With this in mind the reform intends to halt the formation of new physician owned hospitals and already existing ones will be prevented from expanding.

Existing health plan providers will lose out as the new healthcare will introduce a public option. This will make competition intense, and once there is competition prices tend to go down. This will be good for the general population but not too good for present insurers as their market share will start to dwindle.

The reimbursements to providers of medical equipment has already been cut, and with the health reform there will be further cuts. Manufacturers of these durable medical devices will also see a reduction in their income.

Companies that offer certain types of radiological imaging will see less reimbursements for their services as they will be forced to accept less payment for certain types of imaging. Physician owned imaging companies will also take a hit to prevent doctors from sending unnecessary imaging requests to their companies to reap some benefit at the expense of the bill payer.

Pharmaceutical companies that produce medication by recombinant DNA technology will also take a hit as Congress is working with the food and drug administration to approve generic cheaper versions of these expensive medicines.



Source by Conrad Artio

Leave a Reply

Your email address will not be published. Required fields are marked *

* Checkbox GDPR is required

*

I agree